Kindred Biosciences (KIN) Starts Presentation at LD Micro Main Event
Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company that focuses on the development of therapies for pets. The company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. Kindred Biosciences has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. For more information, visit the company's website at www.kindredbio.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As…







